Literature DB >> 31927585

The impact of pharmaceutical innovation on the burden of disease in Ireland, 2000-2015.

Frank R Lichtenberg1,2.   

Abstract

BACKGROUND: We perform an econometric assessment of the impact that pharmaceutical innovation had on the burden of disease in Ireland.
METHODS: We use a difference-in-differences (or two-way fixed effects) research design: we investigate whether diseases for which more new drugs were launched had larger subsequent reductions in mortality. This design controls for the effects of general economic and societal factors (e.g. income, education, and behavioral risk factors), to the extent that those effects are similar across diseases.
RESULTS: New Chemical Entities launched during 1983-1997 are estimated to have reduced the total number of disability-adjusted life-years (DALYs) lost in 2015 by about 234 600.
CONCLUSIONS: Pharmaceutical expenditure per DALY gained in 2015 from drugs launched during 1983-1997 was €1137, which indicates that the new drugs launched during 1983-1997 were very cost-effective, overall.
© The Author(s) 2020. Published by Oxford University Press on behalf of Faculty of Public Health.

Entities:  

Keywords:  Ireland; innovation; longevity; mortality; pharmaceutical

Mesh:

Substances:

Year:  2020        PMID: 31927585      PMCID: PMC7685853          DOI: 10.1093/pubmed/fdz183

Source DB:  PubMed          Journal:  J Public Health (Oxf)        ISSN: 1741-3842            Impact factor:   2.341


  6 in total

1.  The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.

Authors:  Patricia M Danzon; Y Richard Wang; Liang Wang
Journal:  Health Econ       Date:  2005-03       Impact factor: 3.046

2.  The productivity of health care and health production functions.

Authors:  Cağatay Koç
Journal:  Health Econ       Date:  2004-08       Impact factor: 3.046

3.  What are the respective roles of the public and private sectors in pharmaceutical innovation?

Authors:  Bhaven N Sampat; Frank R Lichtenberg
Journal:  Health Aff (Millwood)       Date:  2011-02       Impact factor: 6.301

4.  The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009.

Authors:  Frank R Lichtenberg
Journal:  Econ Hum Biol       Date:  2013-04-12       Impact factor: 2.184

5.  Funding of US biomedical research, 2003-2008.

Authors:  E Ray Dorsey; Jason de Roulet; Joel P Thompson; Jason I Reminick; Ashley Thai; Zachary White-Stellato; Christopher A Beck; Benjamin P George; Hamilton Moses
Journal:  JAMA       Date:  2010-01-13       Impact factor: 56.272

6.  Cost-effectiveness thresholds: pros and cons.

Authors:  Melanie Y Bertram; Jeremy A Lauer; Kees De Joncheere; Tessa Edejer; Raymond Hutubessy; Marie-Paule Kieny; Suzanne R Hill
Journal:  Bull World Health Organ       Date:  2016-09-19       Impact factor: 9.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.